RedHill Reports Results of Yeliva (opaganib) in P-II Study for COVID-19

 RedHill Reports Results of Yeliva (opaganib) in P-II Study for COVID-19

RedHill Reports Results of Yeliva (opaganib) in P-II Study for COVID-19

Shots:

  • The P-II US study involves assessing Opaganib + SOC vs PBO + SOC in 40 patients requiring oxygen support in a ratio (1:1) and were followed up for ~42days post-treatment initiation
  • The study demonstrated improvement in reaching room air within 14days (52.6% vs 22.2%); improvement in reduction to 50% supplemental oxygen by Day 14 (89.5% vs 66.7%); a higher proportion of patients discharged by Day 14 (73.7% vs 55.6%), reduction in the median total oxygen requirement (AUC) over 14 days (68.0% vs 46.7%)
  • The results from the global P-II/III study in 270 hospitalized patients expected in Q1’21 and an interim DSMB futility analysis is expected in the coming weeks

Click here ­to­ read full press release/ article | Ref: Redhill Bio | Image: PR Newswire UK

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post